Find out more about MSF's operations, mission, and it's principles.
Investigational Ebola treatments are to be tested in West Africa for the first time as part of an international initiative to fast-track trials of the most promising drugs, for the disease that has already led to over 2,600 deaths.
A 14.7 million AED grant from the Wellcome Trust will enable multiple partners around the world, including the International Severe Acute Respiratory and Emerging Infections Consortium (ISARIC), the University of Oxford, Médecins Sans Frontières/Doctors Without Borders (MSF), the World Health Organisation (WHO), Institut Pasteur, Institut Pasteur de Dakar, Fondation Mérieux and the Global Health Network, to quickly establish clinical trials at existing Ebola treatment centres.
The unprecedented outbreak of the virus, one of the most virulent infectious agents known to man, has been declared a threat to international peace and security by the UN Security Council and prompted demands for an urgent response.
In August a WHO expert panel unanimously concluded that in such exceptional circumstances it would be ethical to evaluate unregistered investigational treatments in people with Ebola virus disease.
Several potential interventions have shown promise in the laboratory, in animal studies on non-human primates, and in a small number of cases of compassionate intervention, but none has yet been tested for efficacy and safety in humans with Ebola.
Any new drug needs to be evaluated within the rigorous settings of a clinical trial to assess whether it is doing more harm or good.
Led by Dr Peter Horby of the Centre for Tropical Medicine and Global Health at the University of Oxford and ISARIC, this initiative will now allow candidate Ebola treatments to be assessed rapidly in patients so that those proving safe and effective may be adopted for use as soon as possible.
The funding will be used to establish a clinical trials platform involving the consortium and a number of sites in West Africa where treatments can be formally evaluated in patients with Ebola virus disease.
Together with partner health authorities in affected countries, the consortium will assess which sites are suited for the trials, ensuring that activities do not adversely affect the delivery of patient care, staff welfare and safety, and centre operations.
The WHO will then facilitate access to the treatments, and rapid ethical review and implementation of the trials in affected countries.
The precise details of how the trials will be carried out are being discussed with all stakeholders, and, most importantly, the local communities who would be involved. It is possible that trials will involve both randomised and non-randomised arms.
Several candidate treatments are under consideration and a group of independent experts appointed by WHO will recommend which to prioritise based on factors such as which is likely to work best, the availability of the intervention, the ability to safely administer the intervention in treatment centre settings, and the capacity for manufacture to a useful scale.
A number of pharmaceutical companies including Mapp Biopharmaceutical, Sarepta, and Tekmira are collaborating in the initiative and are providing key data on efficacy, safety, and production abilities for a number of potential treatments.
While awaiting the WHO recommendation on the products to be tested first, the consortium will begin immediately to work with counterparts in affected countries to assess the suitability of potential sites, and establish the infrastructure, staffing and systems of the clinical trials platform.
During this phase investigators will also work with affected communities, local organisations, and national ethical and regulatory agencies to determine the best possible study design that can be achieved under the circumstances of the epidemic.
This latest announcement is part of a series of multi-million pound measures supported by the Wellcome Trust and enabling unparalleled international collaboration across the public, private and not-for-profit sectors to tackle the public health emergency.
These include the trial of a candidate Ebola vaccine in the UK and West Africa, and accelerated funding for humanitarian research into combating the outbreak.
Dr Peter Horby, Associate Professor of Infectious Diseases and Global Health, University of Oxford, said: “The Ebola situation in West Africa is an ongoing tragedy of immense proportions and we urgently need to know whether any of these investigational treatments can save lives.
“In essence we need straightforward clinical trials, as for any drug for any disease, but new ways of working will be needed to provide rapid and reliable answers in perhaps the most challenging outbreak we have ever encountered.
“Effective drugs will not only help individual patients but will also increase community confidence in the value of Ebola treatment centres, thereby improving our chances of controlling the outbreak through isolation and treatment of infectious patients.”
Dr Jeremy Farrar, Director of the Wellcome Trust, said: “It is a huge challenge to carry out clinical trials under such difficult conditions, but ultimately this is the only way we will ever find out whether any new Ebola treatments actually work.
“What’s more, rapid trials, followed by large-scale manufacturing and distribution of any effective treatments, might produce medicines that could be used in this epidemic.
“The Wellcome Trust funding will allow these trials to happen quickly, and in an ethically and scientifically robust setting.”
Dr Marie-Paule Kieny, Assistant Director-General of WHO's Health Systems and Innovation, said: “In order to benefit the broader community, WHO confirmed that it is ethical to offer unregistered therapeutic interventions to Ebola patients in the context of the current outbreak, while ensuring that as much information on their safety and efficacy is collected as possible.
“This platform provides an excellent opportunity to put this recommendation into action.”
Dr Piero Olliaro, Senior Research Manager at TDR, the Special Programme for Research and Training in Tropical Diseases at WHO, said: “This clinical trials platform will make it possible to rapidly test potential treatments in the affected West African countries.
“The data will be openly available, an important step for ongoing scientific investigations. The Wellcome Trust's financial commitment is an important and valuable contribution to helping us find new treatments for this terrible outbreak.”
Dr Helen Jamison, Head of Media Relations, Wellcome Trust
T: +44 (0)20 7611 8866 / +44 (0)20 7611 7329, E: email@example.com
The Wellcome Trust is the world’s second-highest spending charitable foundation, dedicated to achieving extraordinary improvements in human and animal health. We support bright minds in biomedical research and the medical humanities, including public engagement, education and the application of research to improve health. We are independent of both political and commercial interests. www.wellcome.ac.uk
The International Severe Acute Respiratory and Emerging Infection Consortium (ISARIC) is a global initiative aiming to ensure that clinical researchers have the open access protocols and data-sharing processes needed to facilitate a rapid response to emerging diseases that may turn into epidemics or pandemics. The vision of ISARIC is to foster global collaborative patient-oriented research between and during epidemics of rapidly emerging public health threats in order to generate new knowledge, maximise the availability of clinical information, and thereby save lives.
Oxford University’s Medical Sciences Division is one of the largest biomedical research centres in Europe, with over 2,500 people involved in research and more than 2,800 students. The University is rated the best in the world for medicine, and it is home to the UK’s top-ranked medical school. From the genetic and molecular basis of disease to the latest advances in neuroscience, Oxford is at the forefront of medical research. It has one of the largest clinical trial portfolios in the UK and great expertise in taking discoveries from the lab into the clinic. Partnerships with the local NHS Trusts enable patients to benefit from close links between medical research and healthcare delivery. A great strength of Oxford medicine is its long-standing network of clinical research units in Asia and Africa, enabling world-leading research on the most pressing global health challenges such as malaria, TB, HIV/AIDS and flu. Oxford is also renowned for its large-scale studies which examine the role of factors such as smoking, alcohol and diet on cancer, heart disease and other conditions.
Fondation Mérieux, established in 1967, is an independent family foundation, which has public interest status. Its mission is to enhance local capacities in developing countries to reduce the impact of infectious diseases on vulnerable populations. Fondation Mérieux focuses on three objectives:
For more information, please visit: www.fondation-merieux.org
Get a deeper insight into the work of MSF by contacting us.